Welcome to our dedicated page for LENZ THERAPEUTICS news (Ticker: LENZ), a resource for investors and traders seeking the latest updates and insights on LENZ THERAPEUTICS stock.
LENZ Therapeutics, Inc. (Nasdaq: LENZ) is a pharmaceutical company headquartered in San Diego, California, focused on the commercialization of VIZZ (aceclidine ophthalmic solution) 1.44%, which it describes as the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults. The LENZ news feed highlights regulatory milestones, commercial launch updates, licensing agreements and medical community engagement related to this presbyopia therapy.
Visitors to this page can follow company announcements on topics such as FDA approval of VIZZ, the start of professional sample distribution to optometrists and ophthalmologists, and the rollout of commercial product availability through ePharmacy channels and retail pharmacies in the United States. LENZ also issues news about early launch metrics, including the number of eye care professionals prescribing VIZZ and prescription volumes in its initial quarters on the market.
Because LENZ is focused on a single branded product, its news often centers on presbyopia treatment, clinical data from the CLARITY Phase 3 trials, and safety and tolerability information for VIZZ. The company also reports on its participation in investor and medical conferences, where management discusses commercial progress and clinicians present data on aceclidine 1.44% ophthalmic solution and optimal pupil size for miotic treatment of presbyopia.
International expansion is another recurring theme in LENZ news. Press releases describe exclusive commercialization partnerships for VIZZ in the Middle East with Lunatus, a licensing and commercialization agreement with Lotus Pharmaceutical in South Korea and Southeast Asia, and other regional arrangements. Updates on direct-to-consumer initiatives, such as the “Make it VIZZable” campaign featuring Sarah Jessica Parker as brand ambassador, provide additional context on how LENZ is promoting VIZZ to adults living with age-related blurry near vision.
LENZ (Nasdaq: LENZ) reported Q4 and full-year 2025 results and commercial progress for VIZZ® (aceclidine 1.44%), launched October 2025. Q4 product revenue was $1.6 million; cash and marketable securities totaled $292.3 million as of December 31, 2025. The company reported broad prescriber uptake and submitted an MAA to the EMA in March 2026.
LENZ expanded its sales footprint to 117 territories (expected fully deployed Q2 2026), announced ex-U.S. partnerships, and reported 45,000+ paid prescriptions on pace through Q1 2026.
LENZ Therapeutics (Nasdaq: LENZ) will report Q4 and full year 2025 financial results and recent corporate highlights on Tuesday, March 24, 2026, via a live webcast and telephone conference.
The event begins at 8:30 a.m. EDT; a replay will be available on the company's investor website for 30 days.
LENZ (NASDAQ: LENZ) submitted a Marketing Authorization Application to the European Medicines Agency for VIZZ® (aceclidine ophthalmic solution) 1.44% for presbyopia on March 10, 2026. This is the fifth ex‑U.S. regulatory submission for VIZZ and follows U.S. FDA approval in July 2025.
Submission is supported by three randomized Phase 3 CLARITY trials that met all primary and secondary endpoints, showing near‑vision improvement within 30 minutes lasting up to 10 hours and no serious treatment‑related adverse events in over 30,000 treatment days.
LENZ Therapeutics (Nasdaq: LENZ) announced management will present at two investor conferences in early March 2026: TD Cowen on March 2 (Boston) and Leerink Partners on March 10 (Miami).
Both events include fireside chats with live audio webcasts and 1x1 investor meetings; replays will be available on the company website for 12 months.
LENZ (NASDAQ: LENZ) launched the consumer campaign “Make it VIZZable” on Jan 14, 2026, naming Sarah Jessica Parker as brand ambassador for VIZZ (aceclidine ophthalmic solution) 1.44%. The campaign highlights SJP’s personal experience with age-related blurry near vision and demonstrates VIZZ as a prescription, once-daily alternative to reading glasses.
Clinical highlight: in the CLARITY Phase 3 trial, 93% of participants achieved 20/40 or better near vision within 30 minutes, lasting up to 10 hours. VIZZ is available nationwide by prescription; free samples are offered through participating eye doctors and www.VIZZ.com.
LENZ Therapeutics (Nasdaq: LENZ) reported preliminary unaudited results for Q4 2025 and recent corporate updates following the October 2025 launch of VIZZ (aceclidine ophthalmic solution) 1.44% for presbyopia.
Key highlights: first commercial sales in October 2025, broad retail and ePharmacy availability by mid‑November 2025, approximately $1.6 million in net product revenue in Q4 2025, over 20,000 prescriptions filled through Q4, and >6,500 unique prescribing eye care professionals with >55% prescribing multiple times in Q4. In January 2026 LENZ signed an exclusive Middle East commercialization partnership with Lunatus including upfront, milestone payments and a revenue share.
LENZ Therapeutics (NASDAQ: LENZ) and Lunatus announced an exclusive distribution agreement dated January 5, 2026 for VIZZ (aceclidine ophthalmic solution) 1.44% in the Middle East region.
Under the deal LENZ will receive upfront, regulatory and commercial milestone payments plus a significant share of regional revenue tied to a pre-determined minimum product supply price. Lunatus gains exclusive commercialization rights in the United Arab Emirates, Saudi Arabia, Kuwait, Qatar, Bahrain, Oman, Jordan, Lebanon and Iraq. LENZ noted VIZZ is the first FDA-approved aceclidine eye drop for presbyopia, approved July 2025 and commercially available in the U.S. since September 30, 2025. LENZ called Lunatus its fourth commercialization partner for VIZZ.
LENZ Therapeutics (NASDAQ: LENZ) said Lotus Pharmaceutical submitted a New Drug Application (NDA) to the South Korea MFDS for VIZZ to treat presbyopia on December 1, 2025.
The filing uses positive Phase 3 CLARITY data: VIZZ met all primary and secondary near-vision endpoints, improved near vision within 30 minutes with effect up to 10 hours, and showed no serious treatment-related adverse events in > 30,000 treatment days. Under a May 2025 license, LENZ is eligible for up to $125 million in milestones plus tiered double-digit royalties; Lotus holds exclusive rights for South Korea and several Southeast Asian countries.
LENZ Therapeutics (Nasdaq: LENZ) announced management will present at three investor conferences in early December 2025: Piper Sandler on Dec 2, 2025 in New York (fireside chat 3:30pm ET), Evercore on Dec 3, 2025 in Coral Gables (fireside chat 1:20pm ET), and Citi Global Healthcare on Dec 4, 2025 in Miami (fireside chat 10:30am ET).
Each event includes live audio webcasts and 1x1 investor meetings. Webcasts will be available on the company website in the Investors & Media section, with replays accessible for 12 months after each event. The company commercializes VIZZ™ (aceclidine ophthalmologic solution) 1.44%, the first FDA-approved aceclidine eye drop for presbyopia in adults.
LENZ (Nasdaq: LENZ) reported FDA approval of VIZZ (aceclidine 1.44%) on July 31, 2025 and initiated a commercial launch in October 2025 with broad availability expected mid‑Q4 2025. Early uptake includes >2,500 unique prescribers and >5,000 prescriptions filled through October 2025, plus 90% ECP awareness in October. The company reported pro forma cash, cash equivalents and marketable securities of approximately $324.0 million as of September 30, 2025 after utilizing $123.5M ATM capacity in October. LENZ recorded multiple partnership milestones totaling $10 million with CORXEL and an exclusive Canada license to Laboratoires Théa with >b>$70 million potential payments and tiered double‑digit royalties. Net loss for the nine months ended September 30, 2025 was $46.2 million.